FDA approves Afrezza for pediatric diabetes patients

한국어

The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.

MannKind Corporation announced the approval during a call led by CEO Michael Castagna. He described the day as a historic moment for the company, the diabetes community, and young patients. Castagna noted that founder Al Mann had long envisioned the treatment reaching children, and the company is fulfilling that goal.

관련 기사

Illustration showing long COVID patients revitalized by fluvoxamine treatment in a clinical trial, with scientists and physician highlighting study results.
AI에 의해 생성된 이미지

Fluvoxamine eases severe fatigue in long COVID patients

AI에 의해 보고됨 AI에 의해 생성된 이미지

A study shows the antidepressant fluvoxamine reduces severe fatigue in long COVID patients. In a randomized trial of 399 adults, it was compared with metformin and placebo. Physician Judith Bruchfeld describes the findings as interesting.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

AI에 의해 보고됨

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

기술

Dexcom outlines growth plans at 2026 investor day

건강

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

건강

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

AI에 의해 보고됨

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

2026년 06월 14일 20시 53분

France reimburses Mounjaro and Wegovy for severe obesity

2026년 06월 10일 04시 55분

Novo Nordisk heads to South African court over semaglutide copies

2026년 05월 28일 07시 51분

Three million kronor for research on mast cells in asthma

2026년 05월 14일 00시 38분

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

2026년 05월 12일 00시 48분

Semaglutide shows strong weight loss results for adults over 65

2026년 05월 07일 17시 40분

Swedish team restores blood sugar control in diabetic mice

2026년 05월 06일 06시 50분

Innovative Cape Town clinic boosts outcomes for young kidney patients

2026년 04월 16일 15시 29분

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

2026년 04월 13일 22시 13분

FDA approves Travere Therapeutics' FILSPARI for FSGS

2026년 03월 23일 12시 25분

Study recommends treatment for all children with obesity

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부